Brucellosis Vaccines Market Synopsis
Brucellosis Vaccines Market Size Was Valued at USD 242.70 Billion in 2023, and is Projected to Reach USD 371.50 Billion by 2032, Growing at a CAGR of 4.8% From 2024-2032.
Brucellosis vaccines are vaccines which are used in the prevention of brucellosis; a zoonotic disease which is caused by Brucella bacteria which mainly affects animals and can be passed to man through contact with the animals or by ingesting infected products. These vaccines needs to be nurtured to help the livestock producers to cut losses on reproductive problems like abortion and infertility in cattle, sheep and goats. As the importance of food security and public health increases, the progress and dispersion of enhanced vaccines for the disease have become relevant.
The market for Brucellosis vaccines has been progressing steadily over time because of rising global consciousness on zoonotic diseases and how they affect both animals and humankind. A factor that Strengthen the demand for Brucellosis vaccines is that governments in every country are encouraging livestock vaccination within their country’s public health quotas. These efforts have specifically targeted the developing countries especially because most of their population depend on livestock. Among those, the enhancement of the know-how of vaccines, like the development of DNA vaccines, have expanded the prospect of the market in the field.
The market is also defined by strict regulatory measures used to promote and ensure the safety and effectiveness of the vaccines available, that have promoted advancement among producers. International relations between governments, veterinary associations, and drug makers are helping to ensure that anti-Brucellosis vaccines go more smoothly into the countries that experience high occurrences of the disease. Increasing research for veterinary medicine and technology integration and the use of better manufacturing techniques are also factors that add to the continual growth in the market.
Brucellosis Vaccines Market Trend Analysis:
Adoption of DNA Vaccines to Revolutionize the Market
- A primary survivorship phenomenon within the Brucellosis vaccines market is DNA-based vaccines, which seem to be safer because, and lie ahead of different traditional vaccine categories by providing better immune reactions. DNA vaccines begin with gene sequences to trigger immunity and therefore have no risk of using live attenuated or inactivated vaccines. This has been so widely embraced since it offers a professional way of handling different strains of Brucella bacteria, in effect solving the problem of meeting different demands from different regions., additionally, getting technologies of gene editing and molecular biology are improving yielding of cost effective DNA vaccines that may redefine the world’s strategy to combat the Brucellosis.
Rising Demand for Vaccines in Endemic Regions
- Brucellosis and its impact in the developing world and increased technological advancement in vaccines research hence call for more vaccines in affected regions serves as a growth opportunity in the market. Brucellosis is a common illness in Africa, the Middle East, and some parts of Asia; showing the importance of mass vaccination. Global and national authorities have directed funds toward projects that are designed to support attempts to enhance animal health and specifically, minimize the risks of zoonotic disease transmission.
- Awareness of sustainable agriculture and food security has led to the greater part of the available funds being directed towards disease control in the livestock thus leading to the enhanced growth in the market. The continuing growth in the vet network and improvements in the technology of delivering vaccines give the stakeholders in the Brucellosis vaccines market a great chance to meet the demands of these areas.
Brucellosis Vaccines Market Segment Analysis:
Brucellosis Vaccines Market is Segmented on the basis of Type, Vaccine, Application, and Region
By Type, Rbs1 Vaccine segment is expected to dominate the market during the forecast period
- The market for Brucellosis vaccines is expected to witness high growth from the Rbs1 segment in the next forecast period as it has been widely used and tested effective in various parts of the world. Rbs1 vaccines are live attenuated formulations, developed to ensure the strongest possible protection from Brucella abortus which is a primary etiologic agent of the brucellosis. The segment is also provided by the low cost and relative simplicity of its production by which it appeals to livestock farmers as well as veterinary organizations around the globe.
- Rbs1 vaccines have elicited high success rates of the prevention of Brucellosis cases in the actual livestock populations whichexplains why these vaccines are quickly gaining popularity. Since the segment is currently conducting research for improving the formulation of vaccines, the Rbs1 segment will continue to dominate the market mainly due to the increasing demand for affordable vaccines in emerging regions.
By Vaccine, DNA Vaccine segment expected to held the largest share
- The DNA vaccines are expected to command the largest share in the Brucellosis vaccines market mainly due to their advanced technology and its safety. These vaccines are gradually becoming popular with health care providers since they offered differential immunity and minimal side effects which are paramount in veterinary practice. Second, DNA vaccines are easier to produce as well as to scale up to large quantities needed for mass immunization campaign.
- Their usage is most apparent in areas with improved veterinary practices, characteristic of regions with increasing technological uptake. Constant investigation in DNA vaccine technology and new money flow in related segment from major drug manufacturers proves this segment to be capable of driving the entire market over the years to come.
Brucellosis Vaccines Market Regional Insights:
Asia Pacific is Expected to Dominate the Market Over the Forecast period
- The Asia-Pacific had dominance in the Brucellosis vaccines market. It is because of the concentrated number of livestock resources, increasing extent of knowledge on zoonosis, as well as vaccination drives backed by the region government. India and China have been among the countries that have received high investments on its veterinary health facilities hence encouraging the use of Brucellosis vaccines.
- The need to enhance production of livestock, fertilizer and to meet food security needs has put the region as a market hub. The demand for new generation of vaccines as well as enhancing the veterinarian solutions in Asia-Pacific will help to sustain the leading position during the forecast period.
Active Key Players in the Brucellosis Vaccines Market
- Biogenesis Bago (Argentina)
- Ceva Santé Animale (France)
- China Animal Husbandry Group (China)
- Colorado Serum Company (USA)
- Hester Biosciences Limited (India)
- Indian Immunologicals Ltd. (India)
- Incepta Vaccine Ltd. (Bangladesh)
- Intervet Inc. (USA)
- Laboratorios Ovejero (Spain)
- Merck Animal Health (USA)
- Qilu Animal Health Products Co. (China)
- Tecnovax S.A. (Argentina)
- Vaxxinova International B.V. (Netherlands)
- Virbac S.A. (France)
- Zoetis Inc. (USA)
- Other Active Players
|
Brucellosis Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 242.70 Billion |
|
Forecast Period 2024-32 CAGR: |
4.8% |
Market Size in 2032: |
USD 371.50 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Vaccine |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Brucellosis Vaccines Market by Type
4.1 Brucellosis Vaccines Market Snapshot and Growth Engine
4.2 Brucellosis Vaccines Market Overview
4.3 Rbs1 Vaccine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Rbs1 Vaccine: Geographic Segmentation Analysis
4.4 S19 Vaccine
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 S19 Vaccine: Geographic Segmentation Analysis
4.5 Others
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Others: Geographic Segmentation Analysis
Chapter 5: Brucellosis Vaccines Market by Vaccine
5.1 Brucellosis Vaccines Market Snapshot and Growth Engine
5.2 Brucellosis Vaccines Market Overview
5.3 DNA Vaccine
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 DNA Vaccine: Geographic Segmentation Analysis
5.4 Subunit Vaccine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Subunit Vaccine: Geographic Segmentation Analysis
5.5 Vector Vaccine
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Vector Vaccine: Geographic Segmentation Analysis
5.6 Recombinant Vaccine
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Recombinant Vaccine: Geographic Segmentation Analysis
Chapter 6: Brucellosis Vaccines Market by Application
6.1 Brucellosis Vaccines Market Snapshot and Growth Engine
6.2 Brucellosis Vaccines Market Overview
6.3 Cattle
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Cattle: Geographic Segmentation Analysis
6.4 Sheep & Goat
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Sheep & Goat: Geographic Segmentation Analysis
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Brucellosis Vaccines Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 BIOGENESIS BAGO (ARGENTINA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 CEVA SANTÉ ANIMALE (FRANCE)
7.4 CHINA ANIMAL HUSBANDRY GROUP (CHINA)
7.5 COLORADO SERUM COMPANY (USA)
7.6 HESTER BIOSCIENCES LIMITED (INDIA)
7.7 INDIAN IMMUNOLOGICALS LTD. (INDIA) INCEPTA VACCINE LTD. (BANGLADESH)
7.8 INTERVET INC. (USA)
7.9 LABORATORIOS OVEJERO (SPAIN)
7.10 MERCK ANIMAL HEALTH (USA)
7.11 QILU ANIMAL HEALTH PRODUCTS CO. (CHINA)
7.12 TECNOVAX S.A. (ARGENTINA)
7.13 VAXXINOVA INTERNATIONAL B.V. (NETHERLANDS)
7.14 VIRBAC S.A. (FRANCE)
7.15 ZOETIS INC. (USA)
7.16 OTHER ACTIVE PLAYERS
Chapter 8: Global Brucellosis Vaccines Market By Region
8.1 Overview
8.2. North America Brucellosis Vaccines Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Type
8.2.4.1 Rbs1 Vaccine
8.2.4.2 S19 Vaccine
8.2.4.3 Others
8.2.5 Historic and Forecasted Market Size By Vaccine
8.2.5.1 DNA Vaccine
8.2.5.2 Subunit Vaccine
8.2.5.3 Vector Vaccine
8.2.5.4 Recombinant Vaccine
8.2.6 Historic and Forecasted Market Size By Application
8.2.6.1 Cattle
8.2.6.2 Sheep & Goat
8.2.6.3 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Brucellosis Vaccines Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Type
8.3.4.1 Rbs1 Vaccine
8.3.4.2 S19 Vaccine
8.3.4.3 Others
8.3.5 Historic and Forecasted Market Size By Vaccine
8.3.5.1 DNA Vaccine
8.3.5.2 Subunit Vaccine
8.3.5.3 Vector Vaccine
8.3.5.4 Recombinant Vaccine
8.3.6 Historic and Forecasted Market Size By Application
8.3.6.1 Cattle
8.3.6.2 Sheep & Goat
8.3.6.3 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Brucellosis Vaccines Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Type
8.4.4.1 Rbs1 Vaccine
8.4.4.2 S19 Vaccine
8.4.4.3 Others
8.4.5 Historic and Forecasted Market Size By Vaccine
8.4.5.1 DNA Vaccine
8.4.5.2 Subunit Vaccine
8.4.5.3 Vector Vaccine
8.4.5.4 Recombinant Vaccine
8.4.6 Historic and Forecasted Market Size By Application
8.4.6.1 Cattle
8.4.6.2 Sheep & Goat
8.4.6.3 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Brucellosis Vaccines Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Type
8.5.4.1 Rbs1 Vaccine
8.5.4.2 S19 Vaccine
8.5.4.3 Others
8.5.5 Historic and Forecasted Market Size By Vaccine
8.5.5.1 DNA Vaccine
8.5.5.2 Subunit Vaccine
8.5.5.3 Vector Vaccine
8.5.5.4 Recombinant Vaccine
8.5.6 Historic and Forecasted Market Size By Application
8.5.6.1 Cattle
8.5.6.2 Sheep & Goat
8.5.6.3 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Brucellosis Vaccines Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Type
8.6.4.1 Rbs1 Vaccine
8.6.4.2 S19 Vaccine
8.6.4.3 Others
8.6.5 Historic and Forecasted Market Size By Vaccine
8.6.5.1 DNA Vaccine
8.6.5.2 Subunit Vaccine
8.6.5.3 Vector Vaccine
8.6.5.4 Recombinant Vaccine
8.6.6 Historic and Forecasted Market Size By Application
8.6.6.1 Cattle
8.6.6.2 Sheep & Goat
8.6.6.3 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Brucellosis Vaccines Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Type
8.7.4.1 Rbs1 Vaccine
8.7.4.2 S19 Vaccine
8.7.4.3 Others
8.7.5 Historic and Forecasted Market Size By Vaccine
8.7.5.1 DNA Vaccine
8.7.5.2 Subunit Vaccine
8.7.5.3 Vector Vaccine
8.7.5.4 Recombinant Vaccine
8.7.6 Historic and Forecasted Market Size By Application
8.7.6.1 Cattle
8.7.6.2 Sheep & Goat
8.7.6.3 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Brucellosis Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 242.70 Billion |
|
Forecast Period 2024-32 CAGR: |
4.8% |
Market Size in 2032: |
USD 371.50 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Vaccine |
|
||
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
